Now consider the authors of that brief summary—which is about as blunt about the dysfunction of the American health care system as it is optimistic about the modern tech that might cure it. They are: Jeffrey Shuren, Bakul Patel, and Scott Gottlieb, writing in a July 2 commentary in the medical journal JAMA.

Shuren, for those of you who don’t obsessively parse org charts of the federal government, oversees the Food and Drug Administration’s Center for Devices and Radiological Health, as he has since 2010. Patel is the associate director for the FDA’s new center on Digital Health. And Gottlieb, of course, is the FDA Commissioner.

Gottlieb, a Trump appointee who has earned high marks all around, has been signaling for a while now that he wants a lighter hand on several areas of drug and device regulation. That’s not news, exactly. But the push to lift the fetters in the fast-growing arena of digital health—particularly when it comes to apps that let consumers better manage their own care as well as record and keep track of their health-related data—is an effort that seems to run up and down the FDA food chain. (Shuren, it’s worth noting, is not a Trumpee, but rather an appointee of former FDA commissioner Margaret Hamburg, who herself was an Obama appointee.) And that suggests at least a quiet revolution at the agency.

So what are the key takeaways from the new laissez-faire stance? For one, the FDA says it plans to largely restrict its hands-on involvement to medical apps and software in which the risk of patient harm, if something goes wrong, is greatest. (While the authors don’t exactly spell it out, the implication is that the FDA may not try to weigh in on applications that are probably harmless, even if they don’t make much of a difference in patient lives.) In other words, the key here is a reasonable assurance of product safety, not efficacy—an essential approach, it would seem, at a time when developers are releasing tens of thousands of mobile health apps each year and where “commercial cycles for new product introductions and modifications” are by necessity compressed, as the JAMA authors note.

Second, and perhaps most interesting, Gottlieb and crew say the FDA will test a pilot “precertification program” in which developers of “software as a medical device” (SaMD) products are accredited as a firm (based on the overall quality of their software design, testing protocols, and presumably track record), rather than insist that each individual product go through its own separate regulatory review. The latter practice, they say, would just “stifle the development of, and access to” innovative apps, even as it provided “limited patient safeguards.”

Remarkably, the FDA is even enlisting an international consortium of regulators to help it sort through the issues and harmonize policies around the globe—a move that seems to fall outside the Trump administration’s standard playbook. The International Medical Device Regulators Forum already has government-agency members from Europe, Australia, Brazil, China, Japan, Russia, Singapore, South Korea, and that longstanding American enemy, Canada.

DIGITAL HEALTH

CRISPR “gene drives” are being tested in animals. If you’re a Brainstorm Health reader, you’ve heard about CRISPR, gene-editing, and all sorts of other scifi-esque advancements in the life sciences. Add another story to the list of potential fever dreams that you should, for the time being, remainextremely skeptical about: creating “gene drives” that could theoretically be used to combat problematic animal populations. But here’s the thing: a number of experts stressed how far there is to go when using this biological tech on a wide scale based on early results. (Nature)

Advertisement

INDICATIONS

President Trump lashes out against Pfizer. On Monday, President Donald Trump unleashed yet another Twitter tirade against drug makers over high prices—in this case singling out U.S. pharmaceutical giant Pfizer and some other pharma companies. “Pfizer & others should be ashamed that they have raised drug prices for no reason,” Trump said in a Twitter post. “They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!”

Here was the general market reaction to the comments, which followed the Trump administration’s announced plans to tackle high drug prices (and a prediction that companies would voluntarily cut those prices): Pfizer stock closed up slightly on the day, and broader indices like the NASDAQ biotech ETF also closed in the green.

THE BIG PICTURE

Doctor burnout. A new study adds to the evidence that burnout and depression among physicians can lead to serious medical errors and lapses in care quality. “Just over 10 percent of doctors reported making a major medical error in the three months before the survey, with about 1 in 20 of these errors being fatal,” according to the survey by Stanford University, which examined more than 6,600 physicians. (ABC News)

The latest premium-raising hit on Obamacare. The Trump administration has decided to halt certain payments to insurers under the Affordable Care Act—a move expected to raise premiums for individuals receiving health insurance in the marketplaces, as health insurers themselves have noted following the move. The issue is complicated; it involves a lawsuit and the Trump administration’s various machinations in dealing with it. CMS Administrator Seema Verma says the administration “has asked the court to reconsider its ruling,” but the decision to freeze payments in the meantime could potentially have a significant effect. (Fortune)